Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2024 · 67 positions · Total reported value $1.46B · Top-10 concentration 60.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2024 13F filing, Eversept Partners, LP disclosed 67 equity positions with a combined reported value of $1.46B. The filing implies a focused portfolio: its ten largest positions account for 60.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were GSK ($165.86M), QQQ ($121.82M), NTRA ($110.47M). By sector, the heaviest allocations are Health Care 78.0%, Industrials 5.1%. Versus the prior quarter, allocation shifted toward Other (+1.2pp), Industrials (+1.0pp) and away from Consumer Discretionary (-0.7pp), Health Care (-1.6pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q3 2024 were BHC ($12.49M), FTRE ($9.16M), ITCI ($9.11M).

Of the 27 positions fully exited versus the prior quarter, the largest were NVO ($20.98M), LLY ($19.22M), ARGX ($14.88M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • BHC BAUSCH HEALTH COS INC · $12.49M
  • FTRE FORTREA HOLDINGS · $9.16M
  • ITCI INTRA-CELLULAR THERAPIES INC · $9.11M
  • BHVN BIOHAVEN LTD · $6.62M
  • FNA PARAGON 28 INC · $5.00M
  • STAA STAAR SURGICAL · $3.39M
  • ZLAB Zai Lab Ltd · $3.26M
  • ZBIO ZENAS BIOPHARMA INC COM · $3.22M

Fully Exited (vs previous quarter)

  • NVO NOVO-NORDISK A S · prev qtr: $20.98M
  • LLY ELI LILLY & CO · prev qtr: $19.22M · history
  • ARGX ARGENX SE · prev qtr: $14.88M
  • XBI SPDR SERIES TRUST · prev qtr: $9.27M
  • VKTX VIKING THERAPEUTICS INC · prev qtr: $7.34M · history
  • PCVX VAXCYTE INC · prev qtr: $7.26M · history
  • CYTK CYTOKINETICS INC · prev qtr: $6.87M
  • OSCR OSCAR HEALTH INC · prev qtr: $4.92M

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 78.0%
Other 15.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.06M $165.86M 11.36%
11.36%
Add
2 249.60K $121.82M 8.35%
8.35%
Reduce
3 870.19K $110.47M 7.57%
7.57%
Reduce
4 2.05M $90.62M 6.21%
6.21%
Hold
5 1.09M $79.53M 5.45%
5.45%
Reduce
6 4.11M $79.03M 5.41%
5.41%
Add
7 469.69K $60.00M 4.11%
4.11%
Add
8 276.27K $58.31M 3.99%
3.99%
Reduce
9 3.23M $58.29M 3.99%
3.99%
Reduce
10 8.78M $53.27M 3.65%
3.65%
Add
11 663.57K $53.04M 3.63%
3.63%
Add
12 129.08K $52.46M 3.59%
3.59%
Reduce
13 130.95K $46.93M 3.21%
3.21%
Reduce
14 60.00K $34.43M 2.36%
2.36%
Add
15 2.07M $32.86M 2.25%
2.25%
Add
16 319.08K $26.12M 1.79%
1.79%
Reduce
17 163.59K $24.35M 1.67%
1.67%
Reduce
18 1.73M $20.04M 1.37%
1.37%
Add
19 445.20K $20.03M 1.37%
1.37%
Reduce
20 564.90K $19.20M 1.31%
1.31%
Reduce
21 471.36K $18.88M 1.29%
1.29%
Add
22 691.23K $15.73M 1.08%
1.08%
Add
23 1.99M $12.53M 0.86%
0.86%
Reduce
24 1.53M $12.49M 0.86%
0.86%
New
25 869.91K $12.17M 0.83%
0.83%
Reduce
26 33.86K $10.72M 0.73%
0.73%
Reduce
27 38.43K $10.68M 0.73%
0.73%
Reduce
28 134.96K $10.16M 0.70%
0.70%
Add
29 19.46K $10.12M 0.69%
0.69%
Add
30 457.97K $9.16M 0.63%
0.63%
New
31 124.49K $9.11M 0.62%
0.62%
New
32 453.06K $7.34M 0.50%
0.50%
Reduce
33 132.54K $6.62M 0.45%
0.45%
New
34 693.26K $6.45M 0.44%
0.44%
Reduce
35 1.84M $6.37M 0.44%
0.44%
Add
36 861.27K $5.85M 0.40%
0.40%
Reduce
37 307.36K $5.10M 0.35%
0.35%
Reduce
38 749.21K $5.00M 0.34%
0.34%
New
39 4.98M $4.91M 0.34%
0.34%
Reduce
40 998.08K $4.71M 0.32%
0.32%
Reduce
41 5.55M $4.60M 0.32%
0.32%
Add
42 168.37K $4.36M 0.30%
0.30%
Add
43 535.40K $4.07M 0.28%
0.28%
Reduce
44 13.67K $3.93M 0.27%
0.27%
Add
45 192.40K $3.76M 0.26%
0.26%
Add
46 10.59K $3.65M 0.25%
0.25%
Reduce
47 68.26K $3.41M 0.23%
0.23%
Add
48 91.20K $3.39M 0.23%
0.23%
New
49 1.29M $3.30M 0.23%
0.23%
Reduce
50 135.22K $3.26M 0.22%
0.22%
New

FAQ

What did Eversept Partners, LP buy in 2024-Q3?

In its 2024-Q3 13F filing, Eversept Partners, LP reported 67 equity positions worth $1.46B in aggregate; its largest disclosed positions were GSK ($165.86M), QQQ ($121.82M), NTRA ($110.47M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.46B of long equity holdings across 67 positions as of 2024-Q3. Top-10 holdings account for 60.1% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →